ICOSLG and mesothelioma: The combination of AdV5/3-D24-ICOSL-CD40L and Pembrolizumab significantly reduced survival in H226, Mero-82 and MSTO-211H human mesothelioma cell lines cultured in vitro, with an increase in immunogenic cell death.